The KCTD1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat human T lymphoblastoid cell line, engineered for constitutive disruption of the KCTD1 gene. This polyclonal pool comprises heterogeneous knockout alleles that collectively abolish KCTD1 protein expression, providing a robust loss-of-function model. The product is suited for functional assays examining KCTD1’s role as a transcriptional repressor and ubiquitin ligase adaptor, enabling dissection of its molecular functions without clonal selection artifacts.
Jurkat cells are an immortalized T lymphoblastoid line originating from a patient with acute T cell leukemia, widely used to study T cell signaling, apoptosis, and cytokine biology. They grow in suspension, are genetically tractable, and express key components of the Wnt/??-catenin signaling and ubiquitin-proteasome pathways, making them a suitable host for CRISPR/Cas9-mediated disruption of KCTD1. Their well-characterized signaling networks facilitate investigation of gene function in a hematopoietic context.
KCTD1 functions as a substrate adaptor for the CUL3-RBX1 E3 ubiquitin ligase complex, directly recruiting targets such as the transcription factor TFAP2A for ubiquitination and proteasomal degradation. It also acts as a transcriptional repressor of Wnt/??-catenin target genes, including MYC and CCND1, via interactions with PCNA. This dual role connects KCTD1 to craniofacial development, neurodevelopmental disorders, and cancers. The knockout model allows dissection of these mechanisms and their downstream effects on cell proliferation and differentiation.
In Jurkat cells, KCTD1 knockout provides a unique platform to explore its regulatory functions within a T-lymphoid environment, where Wnt/??-catenin and TGF-?? signaling intersect with ubiquitin-mediated proteolysis. Although not classically associated with T cell biology, disruption of KCTD1 can reveal context-dependent roles in cell cycle control and survival relevant to leukemia. The polyclonal population minimizes clonal bias, enhancing the model’s utility for unbiased functional screens and drug target validation.
This knockout model supports diverse applications, including functional genomics of the ubiquitin-proteasome system, Wnt pathway regulation, and cancer cell biology. Compatible assays include Western blotting, RT-qPCR, co-immunoprecipitation, TOPFlash reporter assays, cell proliferation and cell cycle flow cytometry, and ubiquitination assays. These tools enable detailed mechanistic studies and validation of therapeutic targets for neurodevelopmental disorders and cancers. For further inquiries, please contact Ascent Research.
